Clinical trials: Pharyngeal Cancer
Nasopharyngeal Carcinoma
Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study
To explore the progression-free survival rate (progression-free survival, PFS), overall survival (OS), objective response rate(objective response rate, ORR) and safety of patients with Sintilimab + GP chemotherapy combined with…
- Trial name
- NCT05417139
- Testing
- Immunotherapy+induction chemotherapy+radiotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
Photon beam radiation is the standard type of radiation used to treat nasopharyngeal carcinoma. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor and leaves the body through healthy…
- Trial name
- NCT00592501
- Testing
- Proton/Photon Radiotherapy, Cisplatin, Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Nasopharyngeal Carcinoma, De-escalation Therapy
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
This prospective trial aims to enroll patients with high-risk stage III-IVA (AJCC 8th, except T3N0) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT06092957
- Testing
- Cisplatin-based induction chemotherapy, Full course of PD-1/PD-L1 blockades, Reduced-dose IMRT
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Chlorhexidine Gel Therapy for Cariogenic Oral Microflora
The goal of this clinical research study is to find out if 1% chlorhexidine gluconate gel will decrease the amount of bacteria that causes tooth decay. Whether the gel is acceptable to patients will also be studied.
- Trial name
- NCT01036412
- Testing
- 1% Chlorhexidine Gluconate Gel, Surveys
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma
Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era
Currently, concurrent chemoradiotherapy with/without sequential chemotherapy is the standard treatment modality for intermediate risk NPC (stage II and T3N0M0) according to the National Comprehensive Cancer Network guideline.
- Trial name
- NCT02633202
- Testing
- IMRT, Cisplatin
- Where
- China
- Volunteers
- 338 people
- Sponsor
- Sun Yat-sen University
Cancer of the Pharynx, Cancer of the Larynx
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
There is no optimal treatment for patients with recurrent head and neck cancer after previous radiation. Chemotherapy alone is not curative and patients survive an average of only 6 to 10 months.
- Conditions
- Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Neck, Paranasal Sinus Neoplasms
- Trial name
- NCT00970502
- Testing
- erlotinib + celecoxib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johnny Kao
Nasopharyngeal Carcinoma
Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements
Plasma Epstein-Barr virus (EBV) DNA will be measured in native plasma samples of nasopharyngeal carcinoma (NPC) patients, respectively, by three medical centers and a qualified laboratory in Southern China, the highest endemic…
- Trial name
- NCT05037357
- Testing
- Plasma EBV DNA qPCR test
- Where
- China
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to preliminarily evaluate the efficacy and safety of chemotherapy plus subsequent loco-regional radiotherapy combined with toripalimab for the de novo metastatic nasopharyngeal carcinoma.
- Trial name
- NCT04398056
- Testing
- Chemotherapy plus radiotherapy and Toripalimab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sun Yat-sen University
Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
This phase II trial studies how well durvalumab and epacadostat work in treating patients with Epstein-Barr virus positive nasopharyngeal cancer that cannot be removed by surgery (unresectable), has come back (recurrent), or has…
- Conditions
- Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma
- Trial name
- NCT04231864
- Testing
- Durvalumab, Epacadostat
- Sponsor
- Alain Algazi
Nasopharyngeal Carcinoma (NPC)
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
The goal of this clinical trial is to determine the maximum tolerated dose and the recommended phase II dose for nab-paclitaxel when administered concurrently with radiotherapy in nasopharyngeal carcinoma.
- Trial name
- NCT06611150
- Testing
- Nab-paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Adherence to Swallowing Exercises in Head and Neck Cancer
The goal of this research study is to help patients complete the swallowing and dental care exercises they are supposed to perform during radiation treatment.
- Trial name
- NCT00761397
- Testing
- Interview, Phone Call, Brochure
- Where
- United States
- Volunteers
- 485 people
- Sponsor
- M.D. Anderson Cancer Center
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
This Window of Opportunity clinical trial will examine the immunologic effects of the study agent HB-201 in the head and neck or cervical cancer, when administered by IV route.
- Trial name
- NCT04630353
- Testing
- HB-201 IV
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Oral Cancer, Hypopharyngeal Cancer
Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients
Background: Head and neck cancer patients are in high risk to suffer from malnourishment, a risk that increase in postoperative condition and with the use of enteral nutrition (EN).
- Trial name
- NCT03934294
- Testing
- Specific acupuncture group, Metoclopramide 10mg, Non-specific acupuncture group
- Where
- Taiwan
- Volunteers
- 28 people
- Sponsor
- China Medical University Hospital
Recurrent Nasopharyngeal Carcinoma
Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
We aim, in this study, to examine whether reduction of FLT PET derived SUV before and after carbon ion radiotherapy can predict the treatment response and survivals for patients with locoregionally recurrent nasopharyngeal…
- Trial name
- NCT03689556
- Testing
- FLT PET/CT
- Volunteers
- 40 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Nasopharyngeal Carcinoma
Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC
The purpose of this study was to evaluate its rationality in real-world data and provide clinical evidence for the refinement of nodal CTV delineation in nasopharyngeal carcinoma(NPC).
- Trial name
- NCT04745741
- Testing
- IB-positive group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
The purpose of this single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of docetaxel and cisplatin combined with Nimotuzumab in the treatment of recurrent and metastatic nasopharyngeal carcinoma
- Trial name
- NCT03708822
- Testing
- Docetaxel and Cisplatin and Nimotuzumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This trial aims to study the role of Ivonescimab combined with chemoradiotherapy in high-Risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07064902
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Acupuncture
Efficacy of Acupuncture in Radiotherapy-induced Dysphagia in Patients With Head and Neck Cancer
Purpose: Rationale: Acupuncture is a therapy for physical activity disorders secondary to nervous diseases, and it may have therapeutic effects on dysphagia caused by radiation therapy.
- Trial name
- NCT03336775
- Testing
- acupuncture
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma
Molecular Mechanism of Nasopharyngeal Carcinoma
EBV, infection process, immortalization, B lymphocytes, Epithelial cells, co-culture Epstein-Barr virus (EBV) belongs to human γ-herpes viruses.
- Trial name
- NCT00155181
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- National Taiwan University Hospital
Dysphagia, Head and Neck Cancer
Feasibility of Early Swallowing and Speech Intervention for Head and Neck Cancer Patients Treated SURGically
Oral cavity cancer (OCC) is one of the most common cancers worldwide, with tongue cancer being one of the most common subtypes. Patients with oral cancers can experience painful swallowing, swallowing difficulty (dysphagia), and…
- Trial name
- ESSI-SURG (NCT06192771)
- Testing
- ESSI-SURG, Standard-of-Care
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.